Analysis of Topoisomerase I/DNA Complexes in Patients Administered Topotecan

Cancer Research

Volumn 55, Issue 10, 1995, Pages 2097-2103

  Subramanian, Deepa ^a   Muller, Mark T ^a   Kraut, Eric ^b   Staubus, Albert ^b   Young, Donn C ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA TOPOISOMERASE; TOPOTECAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA DAMAGE; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; HELA CELLS; HUMAN; LYMPHOMA, NON-HODGKIN; MELANOMA; SUPPORT, U.S. GOV'T, P.H.S.; TOPOTECAN;

EID: 0029041130     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Liu, L. F. DNA topisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351–375, 1989.
2. Osheroff, N. Biochemical basis for the interactions of type I and type II topoisomer-ases with DNA. Pharmacol. Ther., 41: 223–241, 1989.
3. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191–218, 1994.
4. Izban, M. G., and Luse, D. S. Transcription on nucleosomal templates by RNA polymerase II in vitro: inhibition of elongation with enhancement of sequence-specific pausing. Genes Dev., 5: 683–696, 1991.
5. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365–6368, 1989.
6. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919–6924, 1990.
7. Avemann, K., Knippers, R., and Koller, T. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell. Biol., 8: 3026–3034, 1988.
8. Shin, C.G., and Snapka, R. M. Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons. Biochemistry, 29: 10934–10939, 1990.
9. Boothman, D. A., Trask, D. K., and Pardee, A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by 0-lapachone, an activator of topoisomerase I. Cancer Res., 49: 605–612, 1989.
10. Boothman, D. A., Fukunaga, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618–4626, 1994.
11. Muller, M. T., Pfiind, W. P., Mehta, V. B., and Trask, D. K. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J., 4: 1237–1243, 1985.
12. Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J., and Reinberg, D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature (Lond.), 365: 227–232, 1993.
13. Fleischmann, G., Pflugfelder, G., Steiner, E. K., Javaherian, K., Howard, G. C., Wang, J. C., and Elgin, S. C. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc. Natl. Acad. Sci. USA, 81: 6958–6962, 1984.
14. Liu, L. F., and Wang, J. C. Superceding of the DNA template during transcription. Proc. Natl. Acad. Sci. USA, 84: 7024–7027, 1987.
15. Wu, H.-Y., and Liu, L. F. DNA looping alters local DNA conformation during transcription. J. Mol. Biol., 219: 615–622, 1991.
16. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665–697, 1985.
17. Madden, K. R., and Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52: 525–532, 1992.
18. Trask, D. K., DiDonato, J. A., and Muller, M. T. Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J., 3: 671–676, 1984.
19. Gorman, C. M., Moffatt, L. F., and Howard, B. Recombinant genomes which express chloramphenicol acetyl transferase in mammalian cells. Mol. Cell Biol., 2: 1044–1051, 1982.
20. Trask, D. K., and Muller, M. T. Biochemical characterization of topoisomerase I purified from avian erythrocytes. Nucleic Acids Res., 11: 2779–2800, 1983.
21. Gromova, I. I., Kjeldsen, E., Svejstrup, J. Q., Alsner, J., Christiansen, K., and Westergaard, O. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res., 21: 593–600, 1993.
22. Morham, S. G., and Shuman, S. Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I. J. Biol. Chem., 267: 15984–15992, 1992.
23. Trask, D. K., and Muller, M. T. Stabilization of type I topoismerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA, 85: 1417–1421, 1988.
24. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873–14878, 1985.
25. Horwitz, S. B., Chang, C. K., and Grollman, A. P. Studies on camptothecin. I Effects on nucleic acid and protein synthesis. Mol. Pharmacol., 7: 632–644, 1971.
26. Horwitz, S. B., and Horwitz, M. S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res., 33: 2834–2836, 1973.
27. Eng, W. K., Faucette, L. F., Johnson, R. K., and Steraglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34: 755–760, 1988.
28. Nitiss, J., and Wang, J. C. Topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501–7505, 1988.
29. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016–5022, 1989.
30. Shaw, J. L., Blanco, J., and Mueller, G. C. A simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. Anal. Biochem., 65: 125–131, 1974.
31. Muller, M. T., and Mehta, V. B. DNase I hypersensitivity is independent of endogenous topoisomerase II activity during chicken erythrocyte differentiation. Mol. Cell Biol., 8: 3661–3669, 1988.
32. Spitzner, J. R., Chung, I. K., and Muller, M. T. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res., 18: 1–11, 1990.
33. Ebert, S. N., Subramanian, D., Shtrom, S. S., Chung, I. K., Parris, D. S., and Muller, M. T. Association between the pl70 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type 1. J. Virol., 68: 1010–1020, 1994.
34. Taudou, G., Mirambeau, G., Lavenot, C., der-Garabedian, A., Vermeersch, J., and Duguet, M. DNA topoisomerase activities in concanavalin A-stimulated lymphocytes. FEBS Lett., 776: 431–435, 1984.
35. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattera, M. R., Mong, S.-M., O'Leary Bartus, J., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715–720, 1989.
36. Hsiang, Y. H., Liu, L. F., and Wall, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385–4391, 1989.
37. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues an antitumor agents. J. Natl. Cancer Inst., 85: 271–291, 1993.
38. Drewinko, B., Freireich, E. J., and Gottlieb, J. A. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res., 34: 747–750, 1974.